MSB Trading - 2020, page-1733

Firstly it's NOT a drug.

Comprehension fail on that one.

It's a therapy. Which is from stem cells. Doh.

And this works much higher up the physical chain. Immune reactions, unexpected side effects all these are colossal adverse events with massive drain on company funds. Not going to happen because they're all from playing with unknowns including reactions from immune system, and you need a wide cohort to test different DNA reactions.

None of this is needed here.

AND FYI as risk is factored out in terms of the most extreme losses possible. That is, adverse patient consequences. You should at least attempt to understand why.

The standard means of evaluation for DRUG companies doesn't work with MSB.

This is only about proof of efficacy. I can't stress this enough. This is why most of the analysts have it in the much more conservative category of Drugs because they simply cannot shift their mindsets.

I could write a very long post indeed on how wrong your assumptions are, but I have plenty of other things to do. And I'm not sure you deserve it. DYOR for crying out loud. And think!